microdosing a glp 1 THE PCCA BLOG Microdosing GLP-1s: Safety, Dosage, Side

The rates of local, locoregional, and distant breast cancer recurrence in patients taking semagutide and tirzepatide compared to untreated patients were not statistically different [98]

However, I feel strongly that people need to be informed about both the risks, benefits, and limitations of this (or any) medication that they use, which is part of the informed consent process between you and the prescribing professional

But it requires a little planning

These options are intended for supervised use within a structured care model

The investigational therapy demonstrated significant reductions in HbA1c levels, outperforming placebo and active comparators, and contributed to meaningful weight loss in patients inadequately controlled on standard treatments